This study analyzed melanoma prognosis in patients with thicker tumors, focusing on staging accuracy and survival outcomes. The findings highlighted that Breslow thickness remains a critical prognostic factor, with survival rates declining significantly in tumors exceeding 4 mm, and emphasized the importance of accurate substaging for treatment planning.

Breslow thickness is a key determinant of melanoma survival, and accurate measurement is essential for staging and prognosis.

Patients with thick melanomas (>4 mm) require careful multidisciplinary evaluation for adjuvant therapy and surveillance.